Company: AEMD
Filing Date: 2025-06-26
Form Type: 10-K
Source: 0001683168-25-004780
Chunk: 182

Company: AETHLON MEDICAL INC
Filing Date: 2025-06-26
Form: 10-K
Item: Item 1A
Chunk 182
---
An investment in our securities
involves a high degree of risk. You should carefully consider the risks described below as well as the other information in this Annual
Report before deciding to invest in or maintain your investment in our company. The risks described below are not intended to be an all-inclusive
list of all of the potential risks relating to an investment in our securities. Any of the risk factors described below could significantly
and adversely affect our business, prospects, financial condition and results of operations. Additional risks and uncertainties not currently
known or that are currently considered to be immaterial may also materially and adversely affect our business. As a result, the trading
price or value of our securities could be materially adversely affected and you may lose all or part of your investment.

Risks Relating to Our Financial Position and Need for Additional
Capital

We have incurred significant losses and expect to continue to
incur losses for the foreseeable future.

We have never been profitable.
We did not generate any revenue during the fiscal years ended March 31, 2025 and March 31, 2024. In prior fiscal years we did record revenue
from government contracts. We do not currently have any research grants or contracts. It is possible that we may not be able to enter
into future government contracts. Future profitability, if any, will require the successful commercialization of our Hemopurifier technology
or any other product that we develop or from additional government contract or grant income we may obtain. We may not be able to successfully
commercialize the Hemopurifier or any other products, and even if commercialization is successful, we may never be profitable. While we
currently have over $5.5 million in cash and cash equivalents and have been carrying out certain expense reductions since November 2023,
our planned additional expense reductions may not materialize and/or our patient recruitment may occur more rapidly than expected along
with the concomitant increases in expenses; therefore there is substantial doubt that our cash on hand will carry the company for 12 months
beyond the filing date of the financial statements included in this Annual Report.

We do plan to access the equity
markets for additional capital, however, there can be no assurance that we will be able to access such additional capital.

We will require additional financing to
sustain our operations, achieve our business objectives and satisfy our cash obligations, which may dilute the ownership of our existing
stockholders.

We will require significant
additional financing for our operations and for expected additional